Coherus BioSciences Priced, Nasdaq: CHRS
Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
Industry: Health Care
First Day Return: -6.6%
CHRS
Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
| IPO Data | |
|---|---|
| IPO Date | 11/06/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $85 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Redwood City, CA, United States |
| Founded | 2010 |
| Employees at IPO | 46 |
| Website www.coherus.com | |
IPO News for Coherus BioSciences
Coherus BioSciences (CHRS) Performance
